Exposure of Mesenchymal Stem Cells to an Alzheimer’s Disease Environment Enhances Therapeutic Effects

Mesenchymal stem cells (MSCs) have emerged as a promising tool for the treatment of Alzheimer’s disease (AD). Previous studies suggested that coculture human MSCs with AD in an vitro model reduced expression amyloid-beta 42 (A?42) medium well overexpression amyloid-beta- (A?-) degrading enzymes such neprilysin (NEP). We focused on role primed (human Wharton’s jelly-derived mesenchymal (WJ-MSCs) exposed to cell line via system) reducing levels A? and inhibiting death. demonstrated mouse groups treated naïve showed significant reductions death, ubiquitin conjugate levels, but effects were greater MSCs. Also, mRNA sequencing data analysis indicated high TGF-? induced primed-MSCs. Furthermore, transgenic model. These results highlighted environmental preconditioning is strategy reduce death maintain stemness Further, these suggest WJ-MSCs environment may represent novel therapy AD.